COST EFFECTIVENESS OF ORAL PERICALCITOL IN PATIENTS WITH STAGE III-IV CHRONIC KIDNEY DISEASE AND SECONDARY HYPERPARATHYREOSIS
results of clinical trials demonstrate that selective vitamin D receptor agonist paricalcitoldecreases proteinuria in patients with chronic kidney disease (CKD) and hyperparathyreosis.
Kaydedildi:
| Yazar: | |
|---|---|
| Materyal Türü: | Kitap |
| Baskı/Yayın Bilgisi: |
IRBIS LLC,
2015-03-01T00:00:00Z.
|
| Konular: | |
| Online Erişim: | Connect to this object online. |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|
Internet
Connect to this object online.3rd Floor Main Library
| Yer Numarası: |
A1234.567 |
|---|---|
| Kopya Bilgisi 1 | Kütüphanede |